key: cord-0823636-54bd9s6j authors: Hoque, M. Nazmul; Rahman, M. Shaminur; Sarkar, Md. Murshed Hasan; Habib, Md Ahashan; Hossain, M. Anwar; Khan, M. Salim; Islam, Tofazzal title: Metagenomic analysis reveals the abundance and diversity of opportunistic fungal pathogens in the nasopharyngeal tract of COVID-19 patients date: 2022-02-18 journal: bioRxiv DOI: 10.1101/2022.02.17.480819 sha: 1d2f4b5160a0521964a683f97c5d4e84d5607f08 doc_id: 823636 cord_uid: 54bd9s6j The nasopharyngeal tract (NT) of human is a habitat of a diverse microbial community that work together with other gut microbes to maintain the host immunity. In our previous study, we reported that SARS-CoV-2 infection reduces human nasopharyngeal commensal microbiome (bacteria, archaea and commensal respiratory viruses) but increases the abundance of pathobionts. This study aimed to assess the possible changes in the resident fungal diversity by the inclusion of opportunistic fungi due to the infection of SARS-CoV-2 in the NT of humans. Twenty-two (n = 22) nasopharyngeal swab samples (including COVID-19 = 8, Recovered = 7, and Healthy = 7) were collected for RNAseq-based metagenomics analyses. Our results indicate that SARS-CoV-2 infection significantly increased (p < 0.05, Wilcoxon test) the population and diversity of NT fungi with a high inclusion of opportunistic pathogens. We detected 863 fungal species including 533, 445, and 188 species in COVID-19, Recovered, and Healthy individuals, respectively that indicate a distinct microbiome dysbiosis due to the SARS-CoV-2 infection. Remarkably, 37% of the fungal species were exclusively associated with SARS-CoV-2 infection, where S. cerevisiae (88.62%) and Phaffia rhodozyma (10.30%) were two top abundant species in the NT of COVID-19 patients. Importantly, 16% commensal fungal species found in the Healthy control were not detected in either COVID-19 patients or when they were recovered from the COVID-19. Pairwise Spearman’s correlation test showed that several altered metabolic pathways had significant positive correlations (r > 0.5, p < 0.01) with dominant fungal species detected in three metagenomes. Taken together, our results indicate that SARS-CoV-2 infection causes significant dysbiosis of fungal microbiome and alters some metabolic pathways and expression of genes in the NT of human. Findings of our study might be helpful for developing microbiome-based diagnostics, and also devising appropriate therapeutic regimens including antifungal drugs for prevention and control of concurrent fungal coinfections in COVID-19 patients. Author summary The SARS-CoV-2 is a highly transmissible and pathogenic betacoronavirus that primarily enters into the human body through NT to cause fearsome COVID-19 disease. Recent high throughput sequencing and downstream bioinformatic analyses revealed that microbiome dysbiosis associated with SARS-CoV-2 infection are not limited to bacteria, and fungi are also implicated in COVID-19 development in susceptible individuals. This study demonstrates that SARS-CoV-2 infection results in remarkable depletion of NT commensal fungal microbiomes with inclusion of various opportunistic fungal pathogens. We discussed the role of these altered fungal microbiomes in the pathophysiology of the SARS-CoV-2 infection. Our results suggest that dysbiosis in fungal microbiomes and associated altered metabolic functional pathways (or genes) possibly play a determining role in the progression of SARS-CoV-2 pathogenesis. Thus, the identifiable changes in the diversity and composition of the NT fungal population and their related genomic features demonstrated in this study might lay a foundation for better understanding of the underlying mechanism of co-pathogenesis, and the ongoing development of therapeutic agents including antifungal drugs for the resolution of COVID-19 pandemic. symptoms of respiratory illness (S1 Table) . We were able to characterize both common and Recovered humans (Fig 1) . to the sex (male or female) of the study people (Fig 2) . The unique and shared distribution of fungal taxa found in the three metagenome groups 175 is presented by comprehensive Venn diagrams (Fig 3) found to be shared across the given conditions ( Fig 3D) Table) . Despite stronger associations among these 50 species used for phylogenetic tree Table) . Table) . These species were solely present in Healthy humans nasal cavity, and not merely detected in 302 COVID-19 patients samples Moreover, changes in microbiome composition were supported 303 by high bootstrap values (98%-100% for each species) (Fig 9) . Kruskal-Wallis test) in their composition and relative abundances (S1 Fig, S2 Data) . fungal population with inclusion of pathobionts in the NT of human (Fig 3 and 9) . Moreover, we detected a number of microbial genomic features, altered metabolic pathways, and The COVID-19 patients NT fungal microbiomes exhibited a statistically significant higher 387 diversity (both within and between sample diversities) than those of Recovered humans and 388 Healthy controls (Fig 1 and 2) , which supports our hypothesis of dysbiosis and also agree with Subject recruitment and sample collection 544 We collected twenty-two (n=22) nasopharyngeal samples (including COVID-19 = 8, 545 Recovered = 7, and Healthy = 7) from Dhaka city of Bangladesh during May to July, 2020. The suspected patients were diagnosed positive for SARS-CoV-2 infections (COVID-19) 547 through RT-qPCR on an average 4.7 days (range: 2-9 days) after the onset of clinical signs. The confirmed patients were admitted into the dedicated COVID-19 isolation wards. These 549 patients were tested negative for COVID-19 after 17.5 (ranged from11 to 32) days of first 550 confirmation of SARS-CoV-2 infection, and categorized as Recovered humans (S1 Table) . In 551 this study, 68.0% and 32.0% of the selected people were male and female, respectively, and Recovered cases had sole association of 81, 227 and 315 species, respectively, and 65 667 species (highlighted in blue circle) were found to be shared across the study sample groups. More information on the taxonomic result is also available in S1 Data. symbols "****", "***", "**", "*", and "n.s", respectively. symbols "****", "***", "**", "*", and "n.s", respectively. Heatmap showing (A) 763 KEGG orthologues (KOs) and (B) SEED subsystems associated with fungal metabolism in 764 COVID-19 and Recovered metagenomes Evaluation of SARS-CoV-2 812 entry, inflammation and new therapeutics in human lung tissue cells Genomic diversity and 815 evolution, diagnosis, prevention, and therapeutics of the pandemic COVID-19 disease The proximal origin of SARS-CoV-818 2 Dysbiosis of oral and gut 820 microbiomes in SARS-CoV-2 infected patients in Bangladesh: elucidating the role of 821 opportunistic gut microbes The central role of the nasal 823 microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 824 infection Acute respiratory failure in COVID-19: is it "typical SARS-CoV-2 infection reduces 827 human nasopharyngeal commensal microbiome with inclusion of pathobionts Diversity and genomic 830 determinants of the microbiomes associated with COVID-19 and non-COVID respiratory 831 diseases On the 833 whereabouts of SARS-CoV-2 in the human body: A systematic review Microbial co-infections in 836 COVID-19: Associated microbiota and underlying mechanisms of pathogenesis The role of co-infections and secondary infections in patients with 839 COVID-19 Nosocomial 841 infections associated to COVID-19 in the intensive care unit: clinical characteristics and 842 outcome Clinical features and short-term outcomes of 844 221 patients with COVID-19 in Wuhan The epidemiology and clinical characteristics 846 of co-infection of SARS-CoV-2 and influenza viruses in patients during COVID-19 outbreak CoV-2 and influenza virus co-infection Bacterial and fungal infections among patients 851 with SARS-CoV-2 pneumonia Fungal infections in 853 mechanically ventilated patients with COVID-19 during the first wave: the French multicentre 854 MYCOVID study. The Lancet Respiratory Medicine Invasive 858 aspergillosis in patients admitted to the intensive care unit with severe influenza: a 859 retrospective cohort study Mucormycosis: A deadly black fungus infection 861 among COVID-19 patients in India A systematic review on SARS-CoV-2-associated 863 fungal coinfections COVID-19-associated mucormycosis: 865 Evidence-based critical review of an emerging infection burden during the pandemic's second 866 wave in India Epidemiological and clinical characteristics of 868 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Fungal co-infections associated with global COVID-19 pandemic: a 871 clinical and diagnostic perspective from China International survey on 873 influenza-associated pulmonary aspergillosis (IAPA) in intensive care units: responses suggest 874 low awareness and potential underdiagnosis outside Europe COVID-19 associated with pulmonary aspergillosis: A literature review Bacterial co-infections with 878 SARS-CoV-2 Impact of microbial Aetiology on mortality in severe 880 community-acquired pneumonia Oral microbiome and SARS-CoV-2: beware of lung 882 co-infection Prevalence and 884 outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a 885 systematic review and meta-analysis The role of bacterial and 887 fungal human respiratory microbiota in COVID-19 patients The emerging world of the fungal microbiome Gut microbiota and Covid-19-possible link and implications Gut microbiota composition reflects disease 894 severity and dysfunctional immune responses in patients with COVID-19 The lung-gut axis during viral respiratory infections: The 896 impact of gut dysbiosis on secondary disease outcomes Gut microbiota 898 diversity and C-Reactive Protein are predictors of disease severity in COVID-19 patients Nasopharyngeal Microbiota in 901 SARS-CoV-2 Positive and Negative Patients A comprehensive assessment of 903 demographic, environmental, and host genetic associations with gut microbiome diversity in 904 healthy individuals Metagenomic deep 906 sequencing reveals association of microbiome signature with functional biases in bovine 907 mastitis Dynamic Changes in Microbiome Composition and Genomic 909 Functional Potentials in Bovine Mastitis Nannochloropsis oceanica, a novel natural source 914 of rumen-protected eicosapentaenoic acid (EPA) for ruminants Freeze-dried Nannochloropsis 916 oceanica biomass protects eicosapentaenoic acid (EPA) from metabolization in the rumen of 917 lambs Saccharomyces cerevisiae 919 laryngitis and oral lesions in a patient with laryngeal carcinoma. Case reports in infectious 920 diseases Bloodstream infection 922 by Saccharomyces cerevisiae in two COVID-19 patients after receiving supplementation of 923 Saccharomyces in the ICU Immunity to fungal infections Gut Microbiota Dysbiosis Correlates with Abnormal 926 Immune Response in Moderate COVID-19 Patients with Fever Invasive fungal disease complicating coronavirus disease 2019: when it rains, it 929 spores Characterization and 931 outcome of invasive infections due to Paecilomyces variotii: analysis of patients from the 932 FungiScope® registry and literature reports Penicillioides Infection in a 3-Month-Old Infant with Suspected Cystic Fibrosis: Autopsy Case 936 Report with Review of Literature COVID-19 associated with pulmonary aspergillosis: A literature review Alterations in gut microbiota of patients with 940 COVID-19 during time of hospitalization Previously unknown species of Aspergillus On the safety of Aspergillus oryzae: a 944 review Malassezia spp. yeasts of emerging 946 concern in fungemia Prevalence of Malassezia 948 species on the skin of HIV-seropositive patients Genus-wide comparative genomics of 950 Malassezia delineates its phylogeny, physiology, and niche adaptation on human skin Red yeast (Phaffia rhodozyma) as a 953 source of Astaxanthin and its impacts on productive performance and physiological responses 954 of poultry Preliminary clinical evaluation of 956 toxicity and efficacy of a new astaxanthin-rich Haematococcus pluvialis extract Deregulation of phytoene-β-carotene synthase results in 959 derepression of astaxanthin synthesis at high glucose concentration in Phaffia rhodozyma 960 astaxanthin-overproducing strain MK19 Population genomics 962 shows no distinction between pathogenic Candida krusei and environmental Pichia 963 kudriavzevii: one species, four names The species-specific 965 acquisition and diversification of a K1-like family of killer toxins in budding yeasts of the 966 Saccharomycotina The role of the gut microbiome and its metabolites 968 in metabolic diseases Harnessing the natural anti-glycan immune 971 response to limit the transmission of enveloped viruses such as SARS-CoV-2 IDseq-an open source 974 cloud-based pipeline and analysis service for metagenomic pathogen detection and 975 monitoring Using the metagenomics RAST 977 server (MG-RAST) for analyzing shotgun metagenomes New approach for understanding 980 genome variations in KEGG Insights into the resistome of 982 bovine clinical mastitis microbiome, a key factor in disease complication Microbiome signature and 985 diversity regulates the level of energy production under anaerobic condition phyloseq: an R package for reproducible interactive analysis and 988 graphics of microbiome census data Undersampling and the measurement of beta 990 diversity The authors would like to thank those who provided us the samples. The authors declare no competing interests. Data availability The sequence data reported in this article has been deposited in the National Center for 781 Biotechnology Information (NCBI) under BioProject accession number PRJNA720904.